All In Biotech

Drug Trial Radar · NCT00000857

A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3

A Phase I, Double-Blind, Randomized, Placebo-Controlled Trial of Recombinant Human Interleukin-12 (rhIL-12) in HIV-Infected Subjects With Less Than 50 CD4+ T Cells and Subjects With 300-500 CD4+ T Cells

Last checked: Nov 20, 2026Latest source record: Oct 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

65

Actual

Start

Not stated

Primary completion

Not stated

Study completion Jun 2001

Sponsor

Sponsor type
NIH
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the tolerance and effectiveness of rhIL-12 in HIV-positive patients with CD4 cell counts less than 50 cells/mm3 versus 300-500 cells/mm3. This study will look at the ability of rhIL-12 to boost the immune system against HIV and HIV-associated bacterial infections in these patients. IL-12 is found naturally in the body and rhIL-12 is the commercially produced version. IL-12 may enhance anti-HIV immune system activity by increasing the number of cells that fight infection. IL-12 may also increase the body's ability to fight bacterial infections such as Mycobacterium avium complex (MAC).

Conditions

  • HIV Infections

Interventions

  • Interleukin-12Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA CARE Center CRS

    Los Angeles, California

  • USC CRS

    Los Angeles, California

  • Stanford CRS

    Palo Alto, California

  • Ucsf Aids Crs

    San Francisco, California

  • Harbor-UCLA Med. Ctr. CRS

    Torrance, California

  • Northwestern University CRS

    Chicago, Illinois

  • Rush Univ. Med. Ctr. ACTG CRS

    Chicago, Illinois

  • Weiss Memorial Hosp.

    Chicago, Illinois

  • Indiana Univ. School of Medicine, Infectious Disease Research Clinic

    Indianapolis, Indiana

  • Massachusetts General Hospital ACTG CRS

    Boston, Massachusetts

  • Beth Israel Deaconess Med. Ctr., ACTG CRS

    Boston, Massachusetts

  • NY Univ. HIV/AIDS CRS

    New York, New York

  • Univ. of Rochester ACTG CRS

    Rochester, New York

  • Unc Aids Crs

    Chapel Hill, North Carolina

  • Hosp. of the Univ. of Pennsylvania CRS

    Philadelphia, Pennsylvania

  • University of Washington AIDS CRS

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.